Nanoparticle-based development for HIV-1 biomolecule delivery

NIH Pandemic-Era Grants

Pandemic Era Grants

2021

↗ Live URL (may be dead)

Document text

Principal Investigator: THOMAS  HASSELL
Organization: INTERNATIONAL AIDS VACCINE INITIATIVE
Fiscal Year: 2021
Award: $1,595,794
Funding agency: National Institute of Allergy and Infectious Diseases

NIAID Process Development and Analytical Support for Development of HIV Vaccines: The development of vaccines to prevent the spread of HIV infection is among the National Institute of Allergy and Infectious Diseases (NIAID) highest priorities. While advances in immunology and molecular biology continue to offer an expanding array of approaches for the development of new vaccines/products, there is limited capacity and expertise for translational development to move basic research findings into the clinic. To bridge the gap in translational development, NIAID specifically proposes to support two key critical components: process development and analytical characterization activities. This contract will provide targeted specialized expertise and facilities for process development and analytic characterization. These activities are initiated prior to filing an Investigational New Drug (IND) application and continue as part of product development/chemistry, manufacturing, and control (CMC) activities during ongoing clinical trials (Phase 2 and 3). Access to product development activities (manufacturing process development and optimization, analytical characterization and assay development) is intended to facilitate the progression of potential HIV protein vaccines in Phase 1, 2, and 3 clinical trials.

Terms: <AIDS Virus><Acquired Immune Deficiency Syndrome Virus><Acquired Immunodeficiency Syndrome Virus><Basic Research><Basic Science><Chemistry><Clinic><Clinical Trials><Contracting Opportunities><Contracts><Coupling><DNA Molecular Biology><Development><HIV><HIV Infections><HIV vaccine><HIV-1><HIV-I><HIV/AIDS Vaccines><HIV1><HTLV-III Infections><HTLV-III-LAV Infections><Human Immunodeficiency Virus Type 1><Human Immunodeficiency Viruses><Human T-Lymphotropic Virus Type III Infections><Human immunodeficiency virus 1><Immunology><Investigational New Drug Application><LAV-HTLV-III><Lymphadenopathy-Associated Virus><Molecular Biology><NIAID><National Institute of Allergy and Infectious Disease><Phase><Process><Proteins><Surface><Vaccines><Virus-HIV><assay development><base><develop a vaccine><development of a vaccine><developmental><human immunodeficiency virus vaccine><lipid nanoparticle><manufacturing process><manufacturing process development><nano particle><nano-sized particle><nanoparticle><nanosized particle><new vaccines><next generation vaccines><novel vaccines><prevent><preventing><product development><vaccine development><vaccine formulation>